GYRE Stock Analysis: Buy, Sell, or Hold?
GYRE - Gyre Therapeutics, Inc. Common Stock
$5.88
-0.05 (-0.84%)
▼
5d:
-2.81%
30d:
-16.0%
90d:
-21.6%
BUY
HIGH Confidence
Analysis Updated: Jun 15, 2026 12:00 AM ET
Earnings: May 08, 2026
0d
Get Alerted When GYRE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: GYRE shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: GYRE shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: GYRE is currently trading at $5.88, which is considered slightly low relative to its 30-day fair value range of $5.75 to $6.82. From a valuation perspective, the stock is trading at a discount (Forward PE: -51.6) compared to its historical average (45.4). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, GYRE is in a strong downtrend. Immediate support is located at $5.44, while resistance sits at $6.66.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $18.67 (+214.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GYRE is in a strong downtrend. Immediate support is located at $5.44, while resistance sits at $6.66.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $18.67 (+214.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$5.75 -
$6.82
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
84.3%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 214.8% below Wall St target ($18.67)
- BULLISH: Market expects only 0% annual growth - appears undervalued
Trading Range Analysis
30-Day Trading Range
$5.75 -
$6.82
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$5.44
Resistance Level
$6.66
Current Trend
Strong Downtrend
Technical data as of
Jun 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-51.57
Wall Street Target
$18.67
(+214.8%)
Revenue Growth (YoY)
2.1%
Earnings Growth (YoY)
166.2%
Profit Margin
-5.4%
PE vs Historical
-51.6 vs 45.4
CHEAP
Share & Embed Analysis
Last updated: June 15, 2026 3:07 PM ET
Data refreshes hourly during market hours. Next update: 4:07 PM
Data refreshes hourly during market hours. Next update: 4:07 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GYRE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$549 | 65 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 62 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 58 HOLD |
|
VKTX
Viking Therapeutics Inc |
STRONG BUY
19 analysts |
$93 | 53 HOLD |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$256 | 59 HOLD |
